JP2020511159A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020511159A5 JP2020511159A5 JP2019570603A JP2019570603A JP2020511159A5 JP 2020511159 A5 JP2020511159 A5 JP 2020511159A5 JP 2019570603 A JP2019570603 A JP 2019570603A JP 2019570603 A JP2019570603 A JP 2019570603A JP 2020511159 A5 JP2020511159 A5 JP 2020511159A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- represented
- il17a
- pharmaceutical composition
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000004965 antibodies Human genes 0.000 claims 8
- 108090001123 antibodies Proteins 0.000 claims 8
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- 102100008982 IL17A Human genes 0.000 claims 5
- 101710003110 IL17A Proteins 0.000 claims 5
- 102100015975 IL17F Human genes 0.000 claims 5
- 101700007032 IL17F Proteins 0.000 claims 5
- 201000010099 disease Diseases 0.000 claims 4
- 241000282414 Homo sapiens Species 0.000 claims 3
- 206010039073 Rheumatoid arthritis Diseases 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- 229920000023 polynucleotide Polymers 0.000 claims 2
- 239000002157 polynucleotide Substances 0.000 claims 2
- 238000003259 recombinant expression Methods 0.000 claims 2
- 206010002556 Ankylosing spondylitis Diseases 0.000 claims 1
- 206010003816 Autoimmune disease Diseases 0.000 claims 1
- 102100002976 CDR2L Human genes 0.000 claims 1
- 101700065988 CDR2L Proteins 0.000 claims 1
- 241000282693 Cercopithecidae Species 0.000 claims 1
- 206010021972 Inflammatory bowel disease Diseases 0.000 claims 1
- 208000002551 Irritable Bowel Syndrome Diseases 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 241000699666 Mus <mouse, genus> Species 0.000 claims 1
- 206010037162 Psoriatic arthropathy Diseases 0.000 claims 1
- 241000700159 Rattus Species 0.000 claims 1
- 201000009596 autoimmune hypersensitivity disease Diseases 0.000 claims 1
- 108091006028 chimera Proteins 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 230000002757 inflammatory Effects 0.000 claims 1
- 200000000018 inflammatory disease Diseases 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 239000000546 pharmaceutic aid Substances 0.000 claims 1
- 201000004681 psoriasis Diseases 0.000 claims 1
- 201000001263 psoriatic arthritis Diseases 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
Claims (14)
- ＩＬ−１７Ａ及びＩＬ−１７Ｆの両者に結合し、ＩＬ−１７Ａ及びＩＬ−１７Ｆの両者の活性を阻害する抗ＩＬ１７Ａ／Ｆ抗体であり、配列番号１で表されるＣＤＲ１Ｈ、配列番号２で表されるＣＤＲ２Ｈ、配列番号３で表されるＣＤＲ３Ｈ、配列番号４で表されるＣＤＲ１Ｌ、配列番号５で表されるＣＤＲ２Ｌ、配列番号６で表されるＣＤＲ３Ｌを含む、抗ＩＬ１７Ａ／Ｆ抗体。
- 配列番号７で表される可変重鎖ドメイン（ＶＨ１−１）並びに配列番号８で表される可変軽鎖ドメイン（ＶＬ５）又は配列番号９で表される可変軽鎖ドメイン（ＶＬ２−１）を含む、請求項１に記載の抗ＩＬ１７Ａ／Ｆ抗体。
- ヒトＩｇＧクラスに属する、請求項１に記載の抗ＩＬ１７Ａ／Ｆ抗体。
- マウス、キメラ又はヒト化バリアントである、請求項１に記載の抗ＩＬ１７Ａ／Ｆ抗体。
- 配列番号１０で表される重鎖と配列番号１１で表される軽鎖とを含む、請求項１に記載の抗ＩＬ１７Ａ／Ｆ抗体。
- 請求項１〜５のいずれか一項に記載の抗ＩＬ１７Ａ／Ｆ抗体をコードするポリヌクレオチド。
- 請求項６に記載のポリヌクレオチドを含む組換え発現ベクター。
- 請求項７に記載の組換え発現ベクターを含む、宿主細胞。
- 被験体におけるＩＬ−１７Ａ及び／又はＩＬ−１７Ｆ関連疾病を治療するための医薬組成物であって、治療に有効な量の請求項１〜５のいずれか一項に記載の抗ＩＬ１７Ａ／Ｆ抗体及び医薬的に許容される賦形剤を含む、医薬組成物。
- 前記ＩＬ−１７Ａ及び／又はＩＬ−１７Ｆ関連疾病が、自己免疫疾患又は炎症性疾患から選択される、請求項９に記載の医薬組成物。
- 前記ＩＬ−１７Ａ及び／又はＩＬ−１７Ｆ関連疾病が乾癬、乾癬性関節炎、強直性脊椎炎、関節リウマチ（ＲＡ）、多発性硬化症（ＭＳ）、全身性エリテマトーデス、変形性関節症又は炎症性腸疾患（ＩＢＤ）から選択される、請求項１０に記載の医薬組成物。
- 被験体が哺乳類である、請求項９に記載の医薬組成物。
- 前記被験体が、ラット、マウス、サル又はヒトから選択される、請求項１２に記載の医薬組成物。
- 被験体がヒトである、請求項１３に記載の医薬組成物。
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/CN2017/076278 WO2018161340A1 (en) | 2017-03-10 | 2017-03-10 | Monoclonal antibody against both il-17a and il-17f and use of the same |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020511159A JP2020511159A (ja) | 2020-04-16 |
| JP2020511159A5 true JP2020511159A5 (ja) | 2020-05-28 |
| JP6876156B2 JP6876156B2 (ja) | 2021-05-26 |
Family
ID=63448085
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019570603A Active JP6876156B2 (ja) | 2017-03-10 | 2017-03-10 | Ｉｌ−１７ａ及びｉｌ−１７ｆに反応するモノクローナル抗体、及びその使用 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US10858427B2 (ja) |
| EP (1) | EP3592771A4 (ja) |
| JP (1) | JP6876156B2 (ja) |
| KR (1) | KR102321861B1 (ja) |
| CN (1) | CN110582512B (ja) |
| AU (1) | AU2017402210B2 (ja) |
| WO (1) | WO2018161340A1 (ja) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110003329B (zh) * | 2019-04-12 | 2022-09-27 | 深圳普瑞金生物药业股份有限公司 | 多肽、il17a/f单域抗体、核苷酸序列及试剂盒 |
| EP4069297A4 (en) * | 2019-12-05 | 2024-02-14 | Seagen Inc | ANTI-AVB6 ANTIBODIES AND ANTIBODY-DRUG CONJUGATES |
| CN112915201B (zh) | 2019-12-06 | 2023-06-27 | 珠海市丽珠单抗生物技术有限公司 | 包含抗il-17抗体的液体制剂 |
| WO2024002145A1 (zh) * | 2022-06-29 | 2024-01-04 | 上海齐鲁制药研究中心有限公司 | 结合il-17a和il-17f的抗体分子及其应用 |
| CN116063493B (zh) * | 2022-07-22 | 2023-09-01 | 贵州省赛尔生物科技有限公司 | 包含抗体和间充质干细胞外泌体的药物组合物及其制备方法 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070160576A1 (en) * | 2001-06-05 | 2007-07-12 | Genentech, Inc. | IL-17A/F heterologous polypeptides and therapeutic uses thereof |
| EP3366702B1 (en) * | 2005-12-13 | 2023-08-09 | Eli Lilly And Company | Anti-il-17 antibodies |
| WO2007106769A2 (en) * | 2006-03-10 | 2007-09-20 | Zymogenetics, Inc. | Antibodies that bind both il-17a and il-17f and methods of using the same |
| ES2463482T3 (es) * | 2007-04-27 | 2014-05-28 | Zymogenetics, Inc. | Anticuerpos que se unen a IL-17a y a IL-17f y procedimientos de uso de los mismos |
| GB0807413D0 (en) | 2008-04-23 | 2008-05-28 | Ucb Pharma Sa | Biological products |
| MX2010012090A (es) | 2008-05-05 | 2011-04-11 | Novimmune Sa | Anticuerpos anti-il 17 a/il-17f de reactividad cruzada y metodos de uso de los mismos. |
| BRPI1011535A2 (pt) * | 2009-04-01 | 2016-03-29 | Genentech Inc | tratamento de distúrbios resistentes à insulina. |
| CA2759848C (en) * | 2009-05-05 | 2018-12-04 | Novimmune S.A. | Anti-il-17f antibodies and methods of use thereof |
| MA34907B1 (fr) * | 2011-01-14 | 2014-02-01 | Ucb Pharma Sa | Molécules d'anticorps se liant à il-17a et il-17f |
| EP3456741B1 (en) * | 2012-05-22 | 2020-12-16 | Bristol-Myers Squibb Company | Il-17a/f il-23 bispecific antibodies and their uses |
| AU2014213599C1 (en) * | 2013-02-08 | 2017-09-07 | Novartis Ag | Anti-IL-17A antibodies and their use in treating autoimmune and inflammatory disorders |
| WO2014161570A1 (en) | 2013-04-03 | 2014-10-09 | Roche Glycart Ag | Antibodies against human il17 and uses thereof |
| WO2015014979A1 (en) | 2013-08-01 | 2015-02-05 | F. Hoffmann-La Roche Ag | Tnfa-il-17 bispecific antibodies |
| CN106336459B (zh) * | 2015-07-13 | 2020-12-08 | 三生国健药业（上海）股份有限公司 | 抗人白细胞介素-17a单克隆抗体、其制备方法和应用 |
-
2017
- 2017-03-10 EP EP17899842.3A patent/EP3592771A4/en active Pending
- 2017-03-10 CN CN201780087699.1A patent/CN110582512B/zh active Active
- 2017-03-10 US US16/491,297 patent/US10858427B2/en active Active
- 2017-03-10 KR KR1020197029557A patent/KR102321861B1/ko active IP Right Grant
- 2017-03-10 WO PCT/CN2017/076278 patent/WO2018161340A1/en unknown
- 2017-03-10 AU AU2017402210A patent/AU2017402210B2/en active Active
- 2017-03-10 JP JP2019570603A patent/JP6876156B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020511159A5 (ja) | ||
| HRP20201633T1 (hr) | Protutijela koja se vežu na il-23 | |
| JP2017079785A5 (ja) | ||
| HRP20191608T1 (hr) | Proteini s ponavljajućim dipeptidom kao terapeutsko ciljno mjesto kod neurodegenerativnih bolesti s ekspanzijom ponavljajućeg heksanukleotida | |
| RU2458071C2 (ru) | Антитела-нейтрализаторы гранулоцитарно-макрофагального колониестимулирующего фактора человека | |
| HRP20191334T1 (hr) | Anti-fcrn antitijela | |
| JP2020018311A5 (ja) | ||
| HRP20161141T1 (hr) | Anti-il-23 protutijela | |
| JP2017163973A5 (ja) | ||
| JP2017184723A5 (ja) | ||
| JP2019054802A5 (ja) | ||
| HRP20180516T1 (hr) | Humanizirana protutijela specifična za protofibrilni oblik amiloidnog-beta peptida | |
| RU2019118359A (ru) | Антитело к cd73 человека | |
| PE20181089A1 (es) | Anticuerpos anti-cd19 humano con alta afinidad | |
| RU2011116927A (ru) | Антитела против интерлейкина 17 (ил-17) человека и их применение | |
| JP2012516158A5 (ja) | ||
| JP2017099391A5 (ja) | ||
| JP2012501669A5 (ja) | ||
| JP2012100667A5 (ja) | ||
| JP2014516945A5 (ja) | ||
| RU2011135422A (ru) | Человеческие анти-il-6 антитела с пролонгированным периодом выведения in vivo и их применение при лечении онкологических, аутоиммунных заболеваний и воспалительных заболеваний | |
| HRP20130877T1 (hr) | Antitijela koja neutraliziraju humani citomegalovirus i njihova primjena | |
| JP2013539369A5 (ja) | ||
| JP2020055849A5 (ja) | ||
| JP2016511277A5 (ja) |